Form 8-K - Current report:
SEC Accession No. 0001558370-25-004511
Filing Date
2025-04-07
Accepted
2025-04-07 08:39:58
Documents
14
Period of Report
2025-04-07
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avte-20250407x8k.htm   iXBRL 8-K 63793
2 EX-99.1 avte-20250407xex99d1.htm EX-99.1 20591
  Complete submission text file 0001558370-25-004511.txt   222628

Data Files

Seq Description Document Type Size
3 EX-101.SCH avte-20250407.xsd EX-101.SCH 3414
4 EX-101.LAB avte-20250407_lab.xml EX-101.LAB 16578
5 EX-101.PRE avte-20250407_pre.xml EX-101.PRE 10781
16 EXTRACTED XBRL INSTANCE DOCUMENT avte-20250407x8k_htm.xml XML 4990
Mailing Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451
Business Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451 617-443-2400
Aerovate Therapeutics, Inc. (Filer) CIK: 0001798749 (see all company filings)

EIN.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40544 | Film No.: 25816466
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)